A study presented at the American Society for Radiation Oncology annual meeting found that high-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
